Product Description
Mechanisms of Action: CB1 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Brazil | Chile | Colombia | European Medicines Agency | Germany | Hungary | India | Ireland | Italy | Peru | Portugal | Slovenia | Sweden | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Obesity, Abdominal|Diabetes, Gestational|Obesity|Insulin Resistance|Other|Overweight|Healthy Volunteers|Dyslipidemia|Inflammation
Phase 3: Type 2 Diabetes|Other|Obesity|Fatty Liver, Alcoholic|Non-alcoholic Fatty Liver Disease|Obesity, Abdominal|Albuminuria|Dyslipidemia|Prediabetic State|Glucose Intolerance|Weight Loss|Arteriosclerosis|Carotid Stenosis|Overweight|Smoking Cessation|Tobacco Use Disorder|Stroke|Myocardial Infarction|Atherosclerosis|Myocardial Ischemia|Coronary Artery Disease|Schizophrenia|Metabolic Syndrome X|Spinal Cord Injuries|Weight Gain|Non-alcoholic Steatohepatitis|Prader-Willi Syndrome|Hepatitis, Alcoholic
Phase 2: Obesity|Polycystic Ovary Syndrome|Hypertension|Marijuana Abuse|Tobacco Use Disorder|Affective Disorders, Psychotic|Alcoholic Intoxication|Schizophrenia|Psychotic Disorders|Spinal Cord Injuries
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2022-001522-30 | P3 |
Active, not recruiting |
Spinal Cord Injuries |
2024-09-29 |
|
| RIMOFATSCI-2 | P2 |
Unknown status |
Spinal Cord Injuries |
2023-11-01 |
|
| RIMOFATSCI-1 | P2 |
Completed |
Spinal Cord Injuries |
2022-06-07 |
|
| Effec Acomplia gastric sensitivity | P4 |
Completed |
Healthy Volunteers |
2021-03-03 |